TEMPI syndrome

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
TEMPI syndrome
SynonymsTelangiectasia-erythrocytosis-monoclonal gammopathy-perinephric-fluid collections-intrapulmonary shunting syndrome

TEMPI Syndrome is an orphan disease where the person share five characteristics from which the acronym is derived: telangiectasias, elevated erythropoietin and erythrocytosis, monoclonal gammopathy, perinephric fluid collection, and intrapulmonary shunting.

Signs and symptoms[edit]

TEMPI Symptom
T Telangiectasias
E Elevated Erythropoietin and Erythrocytosis
M Monoclonal gammopathy
P Perinephric fluid collections
I Intrapulmonary shunting

The patients were all diagnosed at middle age. The symptoms were slowly and steadily progressive. Telangiectasias developed over the face, trunk and arms. Increased serum erythropoietin levels, eventually exceeding 5000 mU /ml, preceded the intrapulmonary shunting and the development of hypoxemia. Sampling of the perinephric fluid revealed a clear, serous fluid with low levels of protein, few leukocytes and no cholesterol or triglycerides. A monoclonal gammopathy was implicated in all patients tested. Spontaneous venous thromboses occurred in some patients, sometimes accompanied with spontaneous intracranial bleeding in the absence of blood vessels malformations.[1]

Cause[edit]

The cause of the syndrome is unknown. The abnormal plasma-cell clone and/or the monoclonal gammopathy are suggested to be triggers of the disease.

Diagnosis[edit]

The diagnosis is based on the five characteristics described above.

Treatment[edit]

Complete and partial disappearance of the symptoms of the TEMPI syndrome was reported with the drugs bortezomib [2], daratumumab [3] and autologous stem cell transplantation [4].

History[edit]

In 2010, the case of a man with unexplained erythrocytosis and perinephric fluid collection as main features was described in the Case Records of the Massachusetts General Hospital.[5] As a consequence two strikingly similar cases were identified and a review of the literature revealed three more patients with similar characteristics and a novel multisystem disease, the TEMPI syndrome, was reported.[1]

As of September 2018, a total of 14 patients worldwide with the TEMPI syndrome have been identified (D.B.Sykes, Personal Communication).

References[edit]

  1. ^ a b Sykes, David B.; Schroyens, Wilfried; O'Connell, Casey (2011). "TEMPI Syndrome – A Novel Multisystem Disease". N Engl J Med. 365 (5): 475–477. doi:10.1056/NEJMc1106670. PMID 21812700.
  2. ^ Schroyens, Wilfried; O'Connell, Casey; Sykes, David B. (2012). "Complete and Partial Responses of the TEMPI Syndrome to Bortezomib". N Engl J Med (367): 778–780. doi:10.1056/NEJMc1205806.
  3. ^ Sykes, David B.; Schroyens, W. (2018). "Complete Responses in the TEMPI Syndrome after Treatment with Daratumumab". N Engl J Med (378 (23)): 2240–2242. doi:10.1056/NEJMc1804415.
  4. ^ Kenderian, S.S..; Rosado, F.G; Sykes, D.B.; Hoyer, J.D.; Lacy, M.Q. (2015). "Long-term complete clinical and hematological responses of the TEMPI syndrome after autologous stem cell transplantation". Leukemia (29 (12)): 2414–2416. doi:10.1038/leu.2015.298.
  5. ^ Bazari, Hasan; Attar, Eyal C.; Dahl, Douglas M.; Uppot, Raul N.; Colvin, Robert B. (2010). "Case Records of the Massachusetts General Hospital. Case 23-2010: A 49-Year-Old Man with Erythrocytosis, Perinephric Fluid Collections, and Renal Failure". N Engl J Med (363): 463–475. doi:10.1056/NEJMcpc1004086.

External links[edit]

Classification
External resources